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EDITORIAL
Sharing the experience among the different component
institutes of Hospital das Clínicas, São Paulo University
Medical School (HCFMUSP) was one of the main goals of
the First Symposium on Clinical Research, held in Septem-
ber 28th, 2005 in São Paulo. The meeting brought together
some of the main investigators of the institution to address
the basic concepts regarding clinical trial participation.
Issues such as the challenge of developing a new drug
through the 4 phases (I to IV), the principles of the Interna-
tional Conference on Harmonization/Good Clinical Practices
(ICH-GCP), and the importance of protocol design were
discussed. The value and meaning of informed consent,
known in Brazil as TCLE (“Termo de consentimento livre
e esclarecido”) was also addressed. Deficient and inconsistent
TCLE writting are still a major reason of disapproval of trial
protocolos by Ethics Committees (EC) in Brazil and in other
countries. The symposium was part of an effort to harmo-
nize and improve all clinical trial-related procedures in the
institution, the largest academic public hospital in Latin
America. In order to consistently increase the participation
in clinical studies, clear rules and guidelines are mandatory.
The main drivers of such a process are the commitment of
the Board of Directors, the strong background of research
and qualification of institution’s investigators, and certainly,
commitment to a fair process by the team during the
implementation.
Clinical trials are essential to the development of bene-
ficial treatments. Human testing must be preceded by pre-
clinical or laboratory research, which typically involves
years of experiments. If this stage is successful, sponsor-
ing companies must provide data to the Food and Drug
Administration (FDA-USA), or similar agencies in other
countries, requesting approval for an Investigational New
Drug (IND) process.1 The clinical testing of experimental
drugs usually goes through 3 phases, with each successive
phase involving a larger number of patients. Phase I stu-
dies are primarily concerned with safety and possible side
effects; normally performed over a few months in a small
number of healthy volunteers, and designed to determine
absorption, distribution, metabolism, and excretion data
(ADME studies). Phase II may last up to 2 or 3 years and
enroll several hundred patients, no longer healthy volun-
teers. Most Phase II trials are randomized, double-blinded,
with one group receiving the experimental drug, while an-
other group receives standard treatment or placebo (con-
trol group). The last pre-approval phase (Phase III) typi-
cally lasts several years; the new drug/procedure is tested
in up to several thousand patients, depending on the field
and/or the disease. Theses studies are usually multicentric,
randomized and double-blinded and should provide a
deeper understanding of the drug effectiveness and benefits
as well as the range of the most common side effects. Upon
satisfactory completion with all relevant items and issues
solved, the company can request formal approval by the
agency through a process called, in the USA, New Drug
Application (NDA). Upon approval, companies obtain au-
thorization for commercialization and can continue con-
ducting late Phase III or Phase IV studies.2 The patient’s
rights and safety are protected in that: (a) the researcher
must obtain approval from an Institutional Review Board
(or an Ethics Committee), normally composed of physi-
cians and lay people and (b) every participating subject
must sign an informed consent, which details the nature
of the trial and everything that may happen to the him or
her during the study.
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The introduction of international guidelines for Good
Clinical Practices (ICH-GCP) in 1996 and the development
of quality infrastructure for research in a wider range of
countries opened broad opportunities to the whole commu-
nity of investigators to participate in clinical trials. Institu-
tions must adapt to these changes to maintain and improve
their attractiveness as a base for industry-sponsored clinical
research. When deciding where to place multicenter inter-
national clinical studies, 3 factors, namely speed, quality, and
cost of research are the main concerns. None of these pa-
rameters is independent, and final decision will depend on
a judgment about overall cost-effectiveness for a particular
project. Several working groups in the developed world have
studied how industry, academia, and government can posi-
tively influence these factors. 3 They have identified solutions
to a number of important issues that should be interesting
to know and to learn from.
There is a growing pressure on the pharmaceutical in-
dustry to reduce product development times. An important
element in the process is the time to include the first pa-
tient (known as FPI). Removal of current and anticipated
impediments to research should be hence implemented as
follows: (i) responsibilities of each player in protocol ap-
proval must be clear; wherever possible, processes should
run in parallel and reviews should be complete within a
defined period of time, all keeping in line with international
and national provisions; (ii) joint training initiatives to im-
prove the quality of submissions to ECs, with development
of training tools by the medical societies and local clini-
cal research teams. The First Symposium for Clinical Re-
search of the HCFMUSP was indeed a step in this direc-
tion.
Regarding quality, an important consideration for pro-
spective clinical trial partners, 2 major areas can be iden-
tified: a) organizational quality, which encompasses the
ability of centers to recruit participants efficiently, and b)
internal quality, or the ability to conduct research in a
proper and ethical fashion to agreed-upon standards. The
application of the ICH-GCP guidelines for trials with medi-
cine-licensing purposes increases the administrative burden
associated with clinical research. 3 This in turn reduces the
time available to investigators to recruit and examine trial
participants. Consequently many sites have failed to recruit
a single patient, and few have met recruitment targets.
The development of clinical research networks is seen
as a positive contribution to improvement and has been
implemented in several countries, including Brazil.4 The
Brazilian government has established requirements for
choosing research centers linked to teaching hospitals to
be included in the National Network for Clinical Trials.
HCFMUSP was one of the sites selected in this process,
and the networking process is already under way.
 Government and University have their own research
goals. However, most of the required infrastructure for their
clinical research is common to that needed by industry;
therefore research infrastructure should be shared. The same
is true regarding training programs on GCP. Additionally,
discussion has revealed a number of areas where govern-
ment and pharmaceutical industry interests would be bet-
ter served by closer collaboration and where a clear un-
derstanding of the responsibilities of both parties might
improve the efficiency and competitiveness of the research
process. Research partnerships have been agreed upon in
several developed countries as a vehicle for advancing these
aspirations.
It must be emphasized that the aim of the work in In-
ternational Harmonization of Clinical Trials is to improve
the health and well being of people around the world. Par-
ticularly, in Brazil, it is intended to ensure that we remain
at, or moves to the forefront of clinical research in terms
of scientific quality, speed of start-up, and cost efficiency.
Success also depends upon increasing public knowledge of
clinical trials, through information about ongoing research
and development, and upon a careful operation of patient
consent arrangements. A guide to collaboration in research
and development between the government and other re-
search funders could bring together the principles of these
collaborative partnerships.
Research protocols may be developed by university gov-
ernment, industry, or others, and should be recorded in a
Clinical Trial Register. In any case, there must be clear
agreement on sponsorship, funding, access to data, publi-
cation/reporting of findings, and intellectual property rights,
ensuring that the steering mechanism has sufficient inde-
pendence to prevent conflicts of interest from arising. In
the complex environment of a major university such as
FMUSP, many situations arise that may be, or may appear
to be, conflicts of interest among employees, investigators
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and sponsors. Complete disclosure and expeditious review
of such potential conflicts is in the best interest of staff,
investigators, and administration. All parties should recog-
nize that disclosure of personal financial interests is vital
to continued public confidence in science, even though this
may appear to be a little uncomfortable. 5 It should be made
quite clear that all parties would benefit from greater trans-
parency and creativity in the management of conflicts of
interest. Dialogue must be initiated or improved through
inclusion of such topics at national meetings and into stu-
dent training programs. Conflict disclosure does not im-
ply that anyone is behaving improperly; and certainly, most
conflicts can be managed.6 In March 2002, the Annals of
Internal Medicine published guidelines for individual phy-
sicians and institutions, strongly recommending that insti-
tutions establish their internal policies.7
The outcome of this work would set the stage for im-
proved cooperation and competitiveness. As stated by
2005 Economy Nobel Prize winners Robert Aumann and
Dividir a experiência clínica dos diferentes institutos per-
tencentes ao Complexo HCFMUSP foi um dos principais
objetivos do I Simpósio de Pesquisa Clínica, que aconteceu
em 28 de setembro último, em São Paulo. No evento estive-
ram presentes alguns dos principais pesquisadores da insti-
tuição, a fim de abordar os conceitos básicos relacionados
à participação em estudos clínicos. Temas como: o desafio
de desenvolver um novo medicamento, através das quatro
fases clínicas (I a IV), os princípios da Conferência Inter-
nacional de Harmonização e as Boas Práticas Clínicas
(ICH-GCP) e a importância do adequado desenho do pro-
tocolo foram discutidos. O valor e o significado do termo
de consentimento livre e esclarecido (TCLE), como é conhe-
cido no Brasil, foram também comentados. Inconsistências
no TCLE são, ainda, a maior razão de reprovação nos Co-
mitês de Ética em Pesquisa (CEPs) no Brasil e em outros
Thomas Schelling, “a minimum of cooperation is a pre-
requisite for a prosperous society”.8 In his book, The Strat-
egy of Conflict (1960),9 Schelling emphasized the fact that
almost all multiperson-decision problems contain a mix-
ture of conflicting and common interests. Regarding con-
flict, commitment, and cooperation, he also mentions that
in the presence of a conflict of interests each party usu-
ally seeks an agreement that is as favorable as possible.
Yet, any agreement is better for both parties than no agree-
ment at all. A more appropriate question might be “what
is a fair outcome for all parties?” Some conflicts of in-
terest may appear so strong as to be insoluble. However,
cooperation is a kind of equilibrium obtained over the
long-term, despite short-term conflicts.8 Therefore, it is
important to understand the other side, because all sides
will become, more than ever, inclined to cooperate when-
ever they face a given situation.9-10 There is a lesson for
all in the game theory, and it does not matter which field
we are talking about.
países. O Simpósio foi uma das ações relacionadas ao pro-
cesso de harmonização referente às pesquisas clínicas que
está em andamento no Hospital das Clínicas da Faculdade
de Medicina da Universidade de São Paulo, o maior hospi-
tal público acadêmico da América Latina. Com o objetivo
de consistentemente aumentar a participação em estudos clí-
nicos, regras claras e diretrizes são mandatórias. Os prin-
cipais condutores de um processo como este são: o compro-
metimento da direção da instituição, o antecedente de ex-
periência em pesquisa e a qualificação dos pesquisadores
da instituição, assim como o seguimento, pelo time, de um
processo “razoável” e respeitoso durante a implementação.
Estudos clínicos são essenciais para o desenvolvimento
de melhores opções de tratamentos. Antes de se iniciar os
testes em seres humanos, extensa experimentação pré-clíni-
ca deve ser conduzida em animais e em laboratório, o que
EM BUSCA DA HARMONIZAÇÃO E QUALIDADE NOS
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